Drugs / Telisotuzumab Adizutecan
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06464692 | Sep 2024 → Dec 2027 expected | colorectal cancer | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05005403 | Nov 2021 → Jul 2027 expected | colorectal cancer, gastroesophageal cancer, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +3 | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT05029882 | Oct 2021 → Nov 2027 expected | colorectal cancer, gastroesophageal adenocarcinoma, non-small cell lung carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06772623 | Mar 2025 → Nov 2027 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07744126 | Sep 2026 → Oct 2029 expected | head and neck squamous cell carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT07769502 | Aug 2026 → Sep 2028 expected | pancreatic ductal adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT07196644 | Dec 2025 → Dec 2030 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT07023289 | Sep 2025 → Nov 2029 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06820463 | Apr 2025 → Mar 2028 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06628310 | Dec 2024 → Oct 2030 expected | esophageal adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06614192 | Nov 2024 → Aug 2027 expected | colorectal cancer | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07490301 | Apr 2026 → Jun 2031 expected | pancreatic ductal adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07155187 | Dec 2025 → Sep 2030 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07005102 | Aug 2025 → Nov 2036 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07821684 | Jan 2027 → Mar 2030 expected | non-small cell lung carcinoma | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07525206 | May 2026 → May 2029 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05982873 | — | cancer | AbbVie | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-10-07 | Vitae Pharmaceuticals, Inc. | Regulatory AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC abbvie.com ↗
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). |
| 2026-05-21 | AbbVie | Results AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline abbvie.com ↗
Data from a Phase 1 basket study of Telisotuzumab adizutecan (Temab-A) , a next-generation c-Met–directed ADC , demonstrated antitumor activity of Temab-A monotherapy in biomarker unselected PROC ( NCT06084481 ) and HNSCC ( NCT06084481 ) patients. |
| 2025-10-13 | AbbVie | Results AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors abbvie.com ↗
Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively. |
| 2025-05-27 | AbbVie | Results AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio abbvie.com ↗
At the time of data cut-off, 54% of responders experienced a ≥6 months duration of response (DoR). |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telisotuzumab Adizutecan | “Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.” PMID 42066233 ↗ May 2026 |
| Known as | ABBV-400 | “An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus...” NCT07525206 ↗4“AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory...” NCT06614192 ↗ “Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.” PMID 42066233 ↗ May 2026 “Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care” NCT07023289 ↗ “Telisotuzumab Adizutecan (ABBV-400)” NCT06464692 ↗ |
| Known as | Temab-A | “Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.” PMID 42066233 ↗ May 2026 |
| Modality | Other / unclassified | “The antibody-drug conjugate Temab-A comprises the c-Met-targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan.” PMID 42066233 ↗ May 2026 |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT05005403 ↗ |
| Target | MET | “The antibody-drug conjugate Temab-A comprises the c-Met-targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan.” PMID 42066233 ↗ May 2026 |